The introduction of second-generation tyrosine kinase inhibitors (TKIs) targeting the protein-tyrosine kinase (PTK) BCR-ABL1 has improved treatment response in chronic myeloid leukemia (CML). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.